Macter International Ltd. · PSX:MACTER
Macter International — FY2023 Earnings Presentation
25 slides from Macter International's earnings presentation, Nov 16, 2023
Slide 1: Cover letter to Pakistan Stock Exchange
November 15, 2023 The General Manager Pakistan Stock Exchange Limited Stock Exchange Building, Stock Exchange Road, Karachi Subject: Corporate Briefing Session of Macter International Limited السالم عليكم Further to our letter dated November 6, 2023 on the above subject, please find attached herew
Slide 2: Macter International Limited Corporate Briefing Session
Macter International Limited Corporate Briefing Session For the year ended June 2023 November 16, 2023
Slide 3: Corporate Information: Shareholding and VIS Credit Rating
Corporate Information Pattern of Shareholding Entity Rating - VIS Credit Rating Shareholding VIS Credit Rating Company Ltd. (VIS) has reaffirmed Shareholder’s Category Percentage the entity ratings of Macter International Limited (Macter or the Company) Individuals 72.63 The long-term rating of ‘A’
Slide 4: Board of Directors
Board of Directors Dr. Amanullah Kassim Chairman Asif Misbah Swaleh Misbah Managing Director & Chief Deputy Managing Director Executive Officer Shiekh Muhammad Syed Anis Ahmed Shiekh Perwez Muhammad Ather Massarat Misbah Jawwad Ahmed Waseem Shah Ahmed Sultan Non-Executive Director Farid Non-Executiv
Slide 5: Mission, Vision & Values
Mission, Vission & Values Mission Macter exists to: 1.Serve humanity by improving health and well-being 2.Facilatating all associates to achieve their potential with dignity; and; 3.Providing a means for an ethical and fair livelihood Values 1.Benevolent Intent Vision We see macter as an integrated
Slide 6: Macter's Journey
Macter’s Journey 2021 2008 Raised Rs 1.1 Bn 1.MOH approval for a 2018 from Right Issue dedicated penicillin Obtained listing 2011 12 facility on PSX Converted to Public 2.P&G initiated contract Limited Company 10 manufacturing 2009 2001 2002 relationship 9 Infusion facility Acquired exclusive Reckit
Slide 7: Manufacturing Facilities
Manufacturing Facilities Particulars Plant I Plant II Location F-216, S.I.T.E, Karachi 75700 E40/A, S.I.T.E, Karachi 75700 Annual 58,700,286 packs 3,082,366 packs Production 2023 Area 1 Acre 1 Acre Facility Area 1 Acre 0.3 Acre General Pharma manufacturing Liquid, Tablet Penicillin Dosage Form Capsu
Slide 8: Economic Indicators
Economic Indicators PKR/USD Parity (Jul’22-Jun’23) 300 285 286 286 CPI (Jul’22-Jun’23) 282 38.0% 40% 266 35.4% 233 236 220 219 222 225 36.4% 217 30% 27.3% 26.6% 27.6% 200 31.5% 29.4% 24.9% 23.8% 24.5% 20% 23.2% 100 10% 0 0% July Aug Sept Oct Nov Dec Jan Feb Mar Apr May June Jul Aug Sept Oct Nov Dec
Slide 9: Macter's Standing: +5 Billion Club
Macter’s Standing: +5 Billion Club
Slide 10: IQVIA Ranking: 26th Overall & 18th In National
IQVIA Ranking: 26th Overall & 18th In National PKR Million 2023 7,569 2022 6,802 2021 5,024 2020 4,133 2019 4,985 0 2,000 4,000 6,000 8,000 Source: IQVIA Q2 MAT 2023
Slide 11: Pakistan Pharma Market Evolution
Pakistan Pharma Market Evolution 747 750 National MNCs 656 PKR Million 201 560 186 500 471 166 423 373 144 129 546 116 470 394 250 328 294 257 0 2018 2019 2020 2021 2022 2023 Source: IQVIA Q2 MAT 2023
Slide 12: Industry Growth Dynamics
Industry Growth Dynamics Pharma Market National MNCs 25 20.3% 19.3% 20 17.4% 15.6% 18.7% 14.2% 17.2% 15 11.3% 15.2% 14.2 13.7% 13.2% 10 12.1% 11.1% 10.8% 10.4% 5 6.4% 0 2018 2019 2020 2021 2022 2023
Slide 13: Pharma Industry Market Share Trend
Pharma Industry Market Share Trend 75% National MNCs 70% 72% 73% 69% 50% 66% 68% 25% 34% 32% 31% 30% 28% 27% 0% 2018 2019 2020 2021 2022 2023
Slide 14: Financial Highlights - For The Year Ended 2023
Financial Highlights - For The Year Ended 2023 Particulars Standalone PKR Million 2023 2022 Variance (%) Sales 6,680 5,311 26% Gross Profit 2,784 2,374 17% Gross Margin 41% 44% Operating Profit 618 528 17% Profit After Tax 392 317 24% EPS 8.58 7.19 19%
Slide 15: Standalone Performance Highlights - 2023
Standalone Performance Highlights - 2023 Net turnover for the year ended 30th June 2023 is reported at Rupees 6,680 Mn grew by 26% versus last year. Our core prescription sales business grew by +30% vs lasy year on account of following; Strong uptake of our recently launched Pegstim (Pegylated GCSF)
Slide 16: Macter Segmented Sales Trend
Macter Segmented Sales trend 7,500 RX Institution Exports Toll 255 PKR Million 652 149 447 149 122 412 5,000 499 320 581 995 1,607 185 283 524 5,324 4,080 3,703 3,358 2,500 3,088 0 FY23 FY22 FY21 FY20 FY19
Slide 17: Net Sales & Profitability Trend
Net Sales & Profitability Trend Sales Profit After Tax % 600 Profit Before Tax 8 PKR Million PKR Million 557 6 6,680 490 400 5,528 5,141 5,311 4 6.0% 331 6.0% 200 4,081 5.0% 2 2.6% 0.3% 123 63 0 FY19 FY20 FY21 FY22 FY23 0 FY19 FY20 FY21 FY22 FY23
Slide 18: Investment Summary Last 5 Years
Investment Summary Last 5 Years Description Rs. in Million TOTAL CAPITAL EXPENDITURE 1601 INFRASTRUCTURE 108 MACHINERY AND EQUIPMENT 544 GAS, ELECTRIC, AIRCONDITIONING & DE-HUMIDIFICATION PLANTS 278 OTHERS 671 During the year under review, the Company has made capital expenditure of Rupess 434 Milli
Slide 19: Macter Top Products - Sales Overview
Macter Top 10 Products - Sales Overview TITAN 819 COBOLMIN 431 RELAXIN 316 VENTICORT 308 231 SANTE PKR in Million PEGSTIM 230 SALMICORT 217 CIPROQUINE 212 MAXIMA 204 MAC EPO 195 0 250 500 750 1,000
Slide 20: Key Brands
Key Brands Te. Eat | brs Pegstim (Peg-filgrastim) = | Momentum / (Etanercept)
Slide 21: New Launches During 2022-2023
New Launches During 2022-2023
Slide 22: Our Toll Customers - Past & Present
Our Toll Customers - Past & Present
Slide 23: Key Challenges & Risks
Key Challenges & Risks Cost inflation and lag in compensatory inflationary price adjustments in DRAP Devaluation in PKR/USD parity Global API and logistics disruption Increasingly stringent local and international regulatory requirements Delays in product registration and pricing Attracting and reta
Slide 24: Future Outlook - Strategic Priorities
Future Outlook - Strategic Priorities Leadership Talent: Build strong talent pipeline and invest in capability building International Markets: Build strong international footprint by entry in new markets Precsription Sales: Grow current brands and launch first to market High Potential molecules and
Slide 25: Thank You Q & A Session
@ Macter Thank You Q & A Session